Scinopharm TaiwanTPE:1789 +2.71%75 Days Payable is 11.80 as of Dec. 2025, which is 31% below its 10-year median of 17.13. GuruFocus rates TPE:1789 with a GF Score™ of 75/100 and a GF Value™ of NT$27.15 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 95.55% on this metric.
The historical rank and industry rank for Scinopharm Taiwan's Days Payable or its related term are showing as below:
TPE:1789'
s Days Payable Range Over the Past 10 Years
Min: 12.67 Med: 17.13 Max: 28.25
Current: 19.66
During the past 13 years, Scinopharm Taiwan's highest Days Payable was 28.25. The lowest was 12.67. And the median was 17.13.
TPE:1789's Days Payable is ranked worse than 95.55% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs TPE:1789: 19.66
Scinopharm Taiwan's Days Payable
declined
from Dec. 2024 (14.39) to Dec. 2025 (11.80).
It may suggest that Scinopharm Taiwanaccelerated paying its suppliers.
Scinopharm Taiwan Days Payable Related Terms
Scinopharm Taiwan Days Payable Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Days Payable distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Scinopharm Taiwan's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Days Payable of 11.80 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Scinopharm Taiwan and its competitors. This is 31% below median its historical median of 17.13. Over the past decade, Scinopharm Taiwan's Days Payable has ranged from 12.67 to 28.25. According to the industry distribution chart, Scinopharm Taiwan ranks #881 out of 922 companies in the Drug Manufacturers industry, placing it in the top 95.6%.
Is Scinopharm Taiwan's Days Payable too high?
Scinopharm Taiwan's current Days Payable of 11.80 is 31% below median its 10-year median of 17.13. Over the past 10 years, this metric has ranged from a low of 12.67 to a high of 28.25. The Drug Manufacturers industry median Days Payable is 90.84. Scinopharm Taiwan's value of 11.80 is 87% below this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #881 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scinopharm Taiwan has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #881 out of 922 companies for Days Payable. This places Scinopharm Taiwan in the lower half of its industry. The industry median Days Payable is 90.84. Scinopharm Taiwan's value of 11.80 is 87% below this benchmark. Historically, Scinopharm Taiwan's own Days Payable has ranged from 12.67 to 28.25 over the past decade. While the company's 10-year median is 17.13 vs. the industry median of 90.84, Scinopharm Taiwan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current Days Payable of 11.80 is 87% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Days Payable is 11.80, which is 31% below median its own 10-year median of 17.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.15, compared to a current price of NT$20.85 — trading 23.2% below its estimated fair value. The current Days Payable is 11.80, which is 31% below median its 10-year median of 17.13 and 87% below the Drug Manufacturers industry median of 90.84. Scinopharm Taiwan's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Days Payable is 11.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.85 is trading 23.2% below its estimated GF Value™ of NT$27.15.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Days Payable: 11.80 (31% below median its 10-year median of 17.13)
GF Value™: NT$27.15 vs. price of NT$20.85 (23.2% below fair value)
Industry Position: 87% below the Drug Manufacturers median (#881 of 922)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
75GF Score
Get the complete analysis for TPE:1789
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
